Compositions and Methods for the Treatment or Prevention of Hepatitis B Virus Infection
AssigneeGlobeImmune, Inc.
InventorsDavid Apelian, Thomas H. King, Zhimin Guo, Claire Coeshott
Life of this patent
Estimating the term…
Abstract
Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof.
Claims46
-56. (canceled)
An immunotherapeutic composition comprising:
- a) a yeast vehicle;
- and
- b) a fusion protein comprising HBV antigens, wherein the HBV antigens consist of:
- i) an HBV surface antigen having an amino acid sequence that is at least 90% identical to positions 1 to 399 of SEQ ID NO:118, positions 1 to 399 SEQ ID NO:116, positions 1 to 399 SEQ ID NO:
- 114 or positions 1 to 399 SEQ ID NO:112;
- and
- ii) an HBV core antigen having an amino acid sequence that is at least 90% identical to positions 400 to 581 of SEQ ID NO:118, positions 400 to 581 SEQ ID NO:116, positions 400 to 581 SEQ ID NO:
- 114 or positions 400 to 581 SEQ ID NO:112;
- wherein the composition elicits an HBV-specific immune response and wherein the fusion protein is expressed by the yeast vehicle.
A yeast expressing a fusion protein comprising HBV antigens, wherein the HBV antigens consist of:
- a) an HBV surface antigen having an amino acid sequence that is at least 90% identical to positions 1 to 399 of SEQ ID NO:118, positions 1 to 399 of SEQ ID NO:116, positions 1 to 399 of SEQ ID NO:
- 114 or positions 1 to 399 of SEQ ID NO:112;
- and
- b) an HBV core antigen having an amino acid sequence that is at least 90% identical to positions 400 to 581 of SEQ ID NO:118, positions 400 to 581 of SEQ ID NO:116, positions 400 to 581 of SEQ ID NO:
- 114 or positions 400 to 581 of SEQ ID NO:112.
A method of treating hepatitis B virus (HBV) infection in a subject, comprising administering to the subject an immunotherapeutic composition comprising:
- a) a yeast comprising a fusion protein;
- b) the fusion protein comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:118, SEQ ID NO:116, SEQ ID NO:
- 114 or SEQ ID NO:112.
A method of treating chronic hepatitis B virus (HBV) infection in a subject comprising administering to the subject an immunotherapeutic composition comprising:
- a) a whole, heat-inactivated yeast from Saccharomyces cerevisiae comprising a fusion protein;
- b) the fusion protein expressed by the yeast, and comprising SEQ ID NO:118, SEQ ID NO:116, SEQ ID NO:
- 114 or SEQ ID NO:112.
A method of treating hepatitis B virus (HBV) infection in a subject, comprising administering to the subject an anti-viral compound and an immunotherapeutic composition comprising:
- a) a yeast comprising a fusion protein
- b) the fusion protein comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:118, SEQ ID NO:116, SEQ ID NO:
- 114 or SEQ ID NO:112.
A method of treating hepatitis B virus (HBV) infection in a subject receiving anti-viral treatment comprising administering to the subject an immunotherapeutic composition comprising:
- a) a yeast comprising a fusion protein
- b) the fusion protein comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:
- SEQ ID NO:118, SEQ ID NO:116, SEQ ID NO:
- 114 or SEQ ID NO:112.
A method of treating chronic hepatitis B virus (HBV) infection in a subject receiving anti-viral treatment comprising administering to the subject an immunotherapeutic composition comprising:
- a) a whole, heat-inactivated yeast from Saccharomyces cerevisiae comprising a fusion protein
- b) the fusion protein expressed by the yeast, and comprising SEQ ID NO:118, SEQ ID NO:116, SEQ ID NO:
- 114 or SEQ ID NO:112.
A method of treating chronic hepatitis B virus (HBV) infection in a subject, comprising administering to the subject an anti-viral compound and an immunotherapeutic composition comprising:
- a) a whole, heat-inactivated yeast from Saccharomyces cerevisiae comprising a fusion protein
- b) the fusion protein expressed by the yeast, and comprising SEQ ID NO:118, SEQ ID NO:116, SEQ ID NO:
- 114 or SEQ ID NO:112.
A recombinant nucleic acid molecule encoding a fusion protein comprising HBV antigens, wherein the HBV antigens consist of:
- i) an HBV surface antigen having an amino acid sequence that is at least 95% identical to positions 1 to 399 of SEQ ID NO:118, positions 1 to 399 of SEQ ID NO:116, positions 1 to 399 of SEQ ID NO:
- 114 or positions 1 to 399 of SEQ ID NO:112;
- and
- ii) an HBV core antigen having an amino acid sequence that is at least 95% identical to positions 400 to 581 of SEQ ID NO:118, positions 400 to 581 of SEQ ID NO:116, positions 400 to 581 of SEQ ID NO:
- 114 or positions 400 to 581 of SEQ ID NO:112.
Dependencies are inferred from the claim text.